SCHEDULE 14A INFORMATION

                Proxy Statement Pursuant to Section 14(a) of the
                        Securities Exchange Act of 1934

Filed by the Registrant |_|
Filed by a Party other than the Registrant |X|
Check the appropriate box:

[ ] Preliminary Proxy Statement         [ ] Confidential, for Use of the
[ ] Definitive Proxy Statement              Commission Only (as permitted by
[X] Definitive Additional Materials         Rule 14a 6(e)(2))
[ ] Soliciting Material Pursuant
    to Section 240.14a-11(c) or
    Section 240.14a-12

                           ICN PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified in its Charter)

                          Iridian Asset Management LLC
                                      and
                         Franklin Mutual Advisers, LLC
- --------------------------------------------------------------------------------
      (Name of Person(s) Filing Proxy Statement, if other than Registrant)
               Payment of Filing Fee (Check the appropriate box):

[X] No fee required

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

    (1) Title of each class of securities to which transaction applies:

        ---------------------------------------------------------------

    (2) Aggregate number of securities to which transaction applies:

        ---------------------------------------------------------------

    (3) Per unit price or other underlying value of transaction computed
        pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
        filing fee is calculated and state how it was determined:

        ---------------------------------------------------------------

    (4) Proposed maximum aggregate value of transaction:

        ---------------------------------------------------------------

    (5) Total fee paid:

        ---------------------------------------------------------------

[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
    0-11(a)(2) and identify the filing for which the offsetting fee was paid
    previously. Identify the previous filing by registration statement number,
    or the Form or Schedule and the date of its filing.

    (1) Amount previously paid:

    -------------------------------------------------------------------

    (2) Form, Schedule or Registration Statement No.:

    -------------------------------------------------------------------

    (3) Filing Party:

    -------------------------------------------------------------------

    (4) Date Filed:

    -------------------------------------------------------------------





The following is the text of a press release issued today by Iridian Asset
Management LLC and Franklin Mutual Advisers, LLC.



FROM:    Iridian Asset Management LLC
         Franklin Mutual Advisers, LLC


            Open Letter to Shareholders of ICN Pharmaceuticals, Inc.
       From Iridian Asset Management LLC and Franklin Mutual Advisers, LLC

Westport, CT, and Short Hills, NJ, May 22, 2002 -- Iridian Asset Management LLC
and Franklin Mutual Advisers, LLC today issued the following open letter to
shareholders of ICN Pharmaceuticals, Inc. (NYSE: ICN):

         Dear Fellow ICN Shareholders:

         As we approach next week's annual meeting at ICN, we want to take this
         opportunity to remind all shareholders of the positions and course of
         action that Iridian and FMA are advocating in our efforts to improve
         shareholder value at ICN. Iridian and FMA are institutional investors
         with significant stakes in ICN, who are exercising our rights as
         shareholders to ensure that all of ICN's shareholders are represented
         by a Board that is professional, independent and committed to working
         solely in the best interests of shareholders.

         Toward that end, we undertook an extensive selection process in order
         to identify three extraordinarily well-qualified nominees to serve as
         directors of ICN. We are confident that their experience as senior
         executives and directors in the pharmaceutical and healthcare
         industries, their expertise in corporate governance matters and their
         willingness to aggressively advocate the shareholders' best interests
         make them ideally suited to the needs of ICN today. It is these three
         independent individuals whom we are asking shareholders to vote for,
         and it is these three who, if elected, will work with their fellow
         directors to bring about positive change at ICN.

         As our proxy materials make clear, Iridian and FMA have advocated to
         these nominees the following courses of action which we believe will be
         in the best interests of all ICN shareholders.

         First, we believe the continuing role and influence of Milan Panic at
         the helm of ICN depresses its share price and deters well-qualified
         executives from pursuing or continuing careers at ICN. As such, action
         must be taken with all deliberate speed to relieve ICN of this burden.
         Our conversations with other shareholders indicate there is broad
         support

         for this action. At the same time, the Board must proceed judiciously
         with its search for new leadership and ensure that a new
         highly-qualified CEO is promptly put in place at ICN. Fortunately, we
         think that an attractive environment currently exists in which to find
         well-qualified pharmaceutical executives.

         Given the company's history of promises unkept, we trust that
         shareholders will not be taken in by ICN's eleventh-hour attempt to
         persuade shareholders that it is proceeding with a 'timely and orderly
         change in leadership.' Had ICN's Board been serious when they announced
         in October 2000 that Milan Panic would be transitioning to a
         non-executive role at ICN Americas, beginning a succession search at
         that time would have been an essential step.

         We believe that, relieved of the leadership of Milan Panic, ICN will be
         able to attract highly successful and highly qualified individuals to
         manage its businesses. We also believe there are executives and
         employees at ICN whose abilities will shine through once relieved of
         Mr. Panic's overshadowing presence.

         The second action we are advocating is for the Board to review the
         composition of the board of directors and management at Ribapharm to
         ensure that they are composed of highly qualified, experienced
         individuals who collectively have the expertise to manage the business
         and strategy of Ribapharm. We expect the ICN Board will work closely
         with Dr. Johnson Lau, the CEO of Ribapharm, toward that end.
         Importantly, we believe the newly constituted Board of ICN must ensure
         that the individuals serving as directors and executives of Ribapharm
         are in both perception and reality truly independent of ICN and Milan
         Panic. Only when the new ICN Board is convinced that these
         prerequisites have been fulfilled should Ribapharm be promptly spun out
         to ICN shareholders on a tax-free basis.

         Thirdly, the Board must review the stalled "restructuring" plan for ICN
         International. We believe that ICN's currently disclosed plan to IPO an
         approximate 40% stake of ICN International would be contrary to
         shareholders' best interests, as it would eliminate the ability to
         distribute this business to ICN shareholders without adverse tax
         consequences. We would encourage the new Board to review the financial
         and strategic plans for ICN International, in detail not available to
         shareholders, and to make a determination as to the most appropriate
         course of action. We would expect it to consider all possible
         alternatives for ICN International, including a sale of all or part of
         the business, a full spin-off to ICN shareholders on a tax-free basis,
         a restructuring of the business to eliminate loss-making operations, or
         some combination of the above.

         Lastly, we believe the Board must work actively with management to
         bring ICN's cost structures down to appropriate levels. We note that
         ICN spent almost $50 million on corporate overhead for a business with
         only $721 million of revenues in 2001. Simple comparisons of ICN's
         financial ratios to similar companies lead us to the conclusion that
         there are significant inefficiencies in the company's operations.

         We are advocating the above actions because we believe they are clearly
         in the best interests of all ICN shareholders. In our opinion, the
         results of last year's annual meeting clearly indicated that ICN
         shareholders support these actions.

         Iridian and FMA have complete confidence in the ability of Rich Koppes,
         Rob O'Leary and Randy Thurman to work with their fellow directors to
         take these and other actions in the best interests of all ICN
         shareholders.

         The past Boards and management of ICN, under the leadership of Milan
         Panic, have in our view failed to live up to their promises to ICN's
         shareholders. The time for real change is now. We must put in place a
         Board which shareholders can trust. By electing three independent
         shareholder-nominated directors, shareholders will deliver three highly
         qualified new Board members with an unmistakable mandate for real
         change at ICN and abilities required to deliver on that mandate.

         We thank the shareholders of ICN in advance for their support at this
         year's annual meeting. Please vote the WHITE proxy card if you have not
         already done so.

         Iridian Asset Management LLC        Franklin Mutual Advisers, LLC

                  David L. Cohen                      David Winters
                    Principal                           President

                                   ----------

         Iridian is an SEC-registered investment adviser located in Westport,
CT. Iridian manages approximately $12 billion for institutional clients, pension
funds, charitable foundations and endowments, and invests primarily in mid-cap
and large-cap U.S. equities.

         Franklin Mutual Advisers, LLC is a subsidiary of Franklin Resources,
Inc. [NYSE:BEN], a global investment organization operating as Franklin
Templeton Investments. Franklin Templeton provides global and domestic
investment management services through its Franklin, Templeton, Mutual Series
and Fiduciary Trust subsidiaries. The San Mateo, CA-based company has over 50
years of investment experience and more than $274 billion in assets under
management as of March 31, 2002. For more information, please call 1-800/DIAL
BEN(R) or visit franklintempleton.com.

In connection with their solicitation of proxies with respect to the 2002 annual
meeting of stockholders of ICN Pharmaceuticals, Inc. ("ICN"), Iridian Asset
Management LLC ("Iridian") and Franklin Mutual Advisers, LLC ("FMA") have filed
with the Securities and Exchange Commission (the "SEC") and disseminated to
stockholders a definitive proxy statement dated April 18, 2002. Stockholders are
advised to read the proxy statement as it contains important information.
Stockholders may obtain a free copy of the proxy statement and other relevant
documents filed with the SEC from the SEC website at www.sec.gov. Stockholders
may also obtain a free copy of Iridian and FMA's proxy statement by contacting
Mackenzie Partners in the manner described below.

                                      # # #


Contact:    For Press:                    For Shareholders and Institutions:
            ----------                    ----------------------------------
            Hedda Nadler                  Mackenzie Partners, Inc.
            Mount & Nadler                Larry Dennedy or Charlie Koons
            Tel:  (212) 759-4440          Tel: Call Collect: (212) 929-5500
                                               Toll Free:  (800) 322-2885